TABLE 2

Summary of Subject Characteristics by Vaccination Group at Enrollment

CharacteristicGroup Aa (Concomitant) (N = 621)Group Ba (Nonconcomitant) (N = 620)
n (%)n (%)
Gender
 Male310 (49.9)310 (50.0)
 Female311 (50.1)310 (50.0)
Age (y)
 Mean (SD)12.2 (1.4)12.1 (1.3)
 Median (range)12.0 (11 to 15)12.0 (11 to 15)
Region
 North America344 (55.4)357 (57.6)
 Latin America277 (44.6)263 (42.4)
Race
 American Indian or Alaska Native60 (9.7)59 (9.5)
 Asian6 (1.0)8 (1.3)
 Black or African American38 (6.1)41 (6.6)
 Multiracial217 (34.9)217 (35.0)
 Native Hawaiian or Other Pacific Islander2 (0.3)5 (0.8)
 White298 (48.0)290 (46.8)
  • a Group A (concomitant administration) received a 0.5-mL dose of 9vHPV vaccine at day 1, month 2, and month 6 and MCV4 and Tdap on day 1; Group B (nonconcomitant administration) received 9vHPV vaccine as above and MCV4 and Tdap at month 1.